


businesswire

# Noxopharm Announces First COVID-19 Patient Treated in Veyonda<sup>®</sup> Study



As the number of COVID-19 cases and deaths continues to rise in most countries, Australian clinical-stage drug development company Noxopharm is pleased to announce treatment of the first patient with its lead pipeline candidate, Veyonda<sup>®</sup>, in the Company's Phase 1 NOXCOVID-1 study.


NOXCOVID-1 is looking at treating those COVID-19 patients hospitalized with moderate lung dysfunction requiring low oxygen support who are at risk of progressing rapidly into requiring intensive care and mechanical ventilation. This rapid progression increasingly is being seen as an inappropriately strong inflammatory reaction known as a cytokine storm by the body's immune system in response to lung damage caused by the virus.

The experimental anti-cancer drug, Veyonda<sup>®</sup>, joins a number of approved and experimental drugs with an antiinflammatory action being tested globally for their ability to block rapid progression of COVID-19 disease from moderate to severe level.




### TRENDING

- Large Parts of Mumbai Hit by Power Outage, Trading Unaffected
- 2. Covid, Taxes Eat Away Diesel's Edge Over Gasoline in India
- **GLOBAL MARKETS-China gains hoist** Asian stocks to two-year peak
- 4. Top Glove Mulls Raising \$1 Billion in Hong Kong Listing
- 5. Reopening Economy Lends Fresh Impetus to Indian Shares



yahoo	finance					2	Sign in	٨
Finance	2020 Election	Watchlists	My Portfolio	Screeners	Premium	Markets	News	Personal Financ
			shown that part		ncer			
	effect of Vey	vonda <sup>®</sup> is an an	ti-inflammatory	effect stemmi	ng			
	from potent	inhibition of th	ne STING signalli	ng pathway.				
	"It's a testan	nent to the skill	l of our scientific	team and ou	r			
	external rese	earch collabora	tors that we hav	e been able to	)			
	identify the	potential appli	cation of Veyond	da $^{ m e}$ in the				
	treatment o	f COVID-19 and	l have been able	to use our pri	or			
	oncology-fo	cused work to a	address this new	and urgent g	obal			
	need," said N	Noxopharm's Cl	nief Medical Offi	cer Gisela				
	Mautner. "It	is our hope tha	at Veyonda <sup>®</sup> will	lessen the sev	erity			
	of COVID-19	and improve tl	he recovery of a	ffected patien	ts			
	worldwide."							
	The NOXCO	/ID-1 trial will e	nroll up to appro	oximately 40				
			ue to be comple		e end			
	of the year.							
	About Noxopharm Noxopharm Limited (ASX:NOX) is an Australian clinical-stage							
	drug develoj	oment compan	y focused on tre	ating cancer v	vith			
	Veyonda <sup>®</sup> , it	s lead drug can	ididate. Noxopha	arm also has a	n			
	active R&D p	program for add	ditional drug can	didates and is	s the			
	major sharel	nolder of U.S. b	iotechnology co	mpany Nyrad	a Inc.			
	(ASX:NYR).							
	View source	version on bus	inesswire.com:					
	https://www	.businesswire.c	om/news/home					
	/202010080	05028/en/						
	Contacts							
	Jane Byram							
	SCORR Mark	eting						
	512-626-2758	3						
	jane@scorrn	narketing.com						
		er to improve our co	g place for users to co community experience					
	suspending article co	ommenting.						

2 of 6






### Benzinga

## Barron's Picks And Pans: Alibaba, AllianceBernstein, Pfizer And More

\* This weekend's Barron's cover story discusses why the lagging industrials could be poised for a decade of outperformance. \* Other featured articles discuss how...

Fox Business Florida man gets 2 years in prison for 'Shark Tank' investment-turned-fraud



The stock market rally is the best of both worlds, but stimult talks are faltering. The 5G Apple iPhone and Amazon Prime Day are on tap.



#### Investor's Business Daily

These Are The 5 Best Stocks To Buy And Watch Now Buying a stock is easy, but buying the right stock without a time-tested strategy is incredibly hard. So what are the best stocks to buy now or put on a watchlist?

:



#### Ad • OshenWatch

#### Australia: Why is Everyone Excited Over This \$49 Smartwatch

Keep healthy and stay in shape while staying connected on the go



#### Benzinga

#### Benzinga's Bulls And Bears Of The Week: AT&T, Apple, Tesla And More

\* Benzinga has examined the prospects for many investor favorite stocks over the past week. \* The FAANG stocks were represented in both the bullish and bearish calls seen this pa...



#### TipRanks

**3 Monster Growth Stocks Gearing up for Gains** Which stocks are always on investors' wish lists? Growth stocks. Time and time again, the pros on the Street point to tickers with above-average growth prospects as must-haves,...

#### Barrons.com

Industrial Stocks Are Getting Ready for 10 Years of Outperformance. Here's How to Play It.

yahoo.	finance					२	Sign in	м
Finance	2020 Election	Watchlists	My Portfolio	Screeners	Premium	Markets	News	Personal Finance
	fer.	Australia	With No Life Insu ns who are currently budget may be able ce	struggling to fit li	fe insurance			

## in the week ahead

Third-quarter earnings season kicks off this week in earnest with a plethora of major banks reporting results.

#### MarketWatch

PMORGAN

#### Want to retire rich? Start by unlearning some conventional wisdom

Fortunately, this "knowledge" never greatly influenced my investment strategy. Meanwhile, Wall Street wants to convince you that you know something about the future, so you actively manage your portfolio and thereby fatten the Street's coffers. In the financial markets, action almost always triggers investme...

#### Barrons.com

#### Nikola Sees New Competition From an Unlikely Source — a Giant Oil Company

French energy giant Total announced an investment in Hyzon Motors, a U.S. company making hydrogen fuel-cell-powered heavy-duty trucks.



#### Ad • Dell

#### Save up to 35%\* on Dell Monitors

Enjoy the view. Love the price. Save up to 35%\* on Dell S Series Monitors that bring every detail to life. Offer ends 29 Oct 2020. T&Cs apply.


:

#### **USA TODAY**

#### If you're close to retirement, here are 3 ways to know you're prepared

Are you on retirement's doorstep but not quite sure you should do it? Here are 3 questions to ask yourself.





#### Benzinga

#### 'Halftime Report' Traders Weigh In On Goldman's **General Electric Call**

On CNBC's "Fast Money Halftime Report," traders discussed Goldman Sachs' bullish call on General Electric Co. (NYSE: GE). Goldman's analyst reinstated the stock with a Buy rating and...

#### Bloomberg

#### Goldman Says Sell Dollar as Odds Firm for Biden Win, Vaccine

(Bloomberg) -- The dollar may tumble to its lows of 2018 on the rising likelihood of Joe Biden winning the U.S. election and progress on a coronavirus vaccine, according to Goldman...

HOME	MAIL NEWS	FINANCE S	SPORTS ENTERTAIN	IMENT LIFE	MORE			
yahoo	finance					Q	Sign in	Ma
Finance	2020 Election	Watchlists	My Portfolio	Screeners	Premium	Markets	News	Personal Finance